Potential proteins identified to target in osteosarcoma treatment
The comprehensive genomic analysis uncovered several osteosarcoma genes which make proteins that could be targets for therapies in the future, such as SEMA4D and SEMA6D.
Researchers using a new Sleeping‑Beauty model have identified several genes that drive osteosarcoma, including SEMA4D and SEMA6D, which are highly expressed in many tumors. Inhibiting SEMA4D may suppress tumor growth, and monoclonal‑antibody therapies against SEMA4D are already in trials for other solid tumors.
Identifying driver genes opens the possibility of new targeted treatments for osteosarcoma, a cancer with poor prognosis and limited options.
Bizonyítékszint: Állatkísérletes. Állatmodellben vizsgálták.
Kapcsolódó jelek
- Systemic Therapy for Osteosarcoma and Ewing Sarcoma
- Future Directions in the Treatment of Osteosarcoma
- Is There a Role for Mifamurtide in Nonmetastatic High‑Grade Osteosarcoma? Results From the Italian Sarcoma Group (ISG/OS‑2) and Spanish Sarcoma Group (GEIS‑33) Trials
- The clinical trial landscape of osteosarcoma: integrating trial data, immunotherapeutic trends, and biomarker insights
- Amputation and Chemotherapy for Osteosarcoma